Back to results
US 8,575,122 B2Granted
Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
AssigneeOtonomy, Inc.
InventorsJay Lichter, Carl Lebel, Fabrice Piu, Andrew M. Trammel
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Claims13
A pharmaceutical otic formulation comprising:
- between about 0.2% to about 20% by weight of an agent that modulates the Atoh1 gene or pharmaceutically acceptable prodrug or salt thereof;
- and
- a thermoreversible gel having a gelation temperature between about room temperature and about body temperature;
- a non-gelation viscosity that allows injection at or about room temperature with a needle having a gauge in the range of 18-31 through the tympanic membrane to an area on or near the round window membrane, and with a gelation viscosity between about 15,000 cP and about 1,000,000 cP;
- wherein the otic formulation provides a sustained release of an effective amount of the agent to the inner ear for a period of from 5 days to 6 months, and wherein the agent is essentially in the form of micronized particles.
2 more elements
A method for treating an otic disease or condition comprising administering to a patient in need thereof a composition, the composition comprising:
- between about 0.2% to about 20% by weight of an agent that modulates the Atoh1 gene or pharmaceutically acceptable prodrug or salt thereof;
- and
- a thermoreversible gel having a gelation temperature between about room temperature and about body temperature;
- a non-gelation viscosity that allows injection at or about room temperature with a needle having a gauge in the range of 18-31 through the tympanic membrane to an area on or near the round window membrane, and with a gelation viscosity between about 15,000 cP and about 1,000,000 cP;
- wherein the composition provides a sustained release of an effective amount of the agent to the inner ear of the patient for a period of from 5 days to 6 months, and wherein the agent is essentially in the form of micronized particles.
2 more elements
Dependencies are inferred from the claim text.